MERCK FOSAMAX SALES REACH $58 MIL. IN U.S. DURING THIRD QUARTER; COZAAR, CRIXIVAN NEAR $50 MIL.; PFIZER ZITHROMAX SALES MORE THAN DOUBLE TO $75 MIL. IN U.S.
Merck's Fosamax is tracking for over $200 mil. in sales in the U.S. during its first full year on the market. Fosamax sales reached $58 mil. in the U.S. for the third quarter, Merck reported Oct. 16. The osteoporosis agent was launched in the U.S. in October 1995, and has generated $141 mil. in sales so far in 1996. Worldwide sales are $79 mil. for the quarter and $189 mil. for the year to date, the company said.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth